Analysts see chronic HCB market doubling as functional cures near
GlobalData expects the chronic hepatitis B therapeutics market across major markets to climb from $1.5 billion in 2024 to $3.2 billion in 2034. The projection reflects rising investment in functional cure candidates, which could shift treatment away from long-term antiviral suppression.
Today’s market is anchored by daily antivirals such as Vemlidy (tenofovir alafenamide) from Gilead Sciences (Nasdaq: GILD), entecavir, and Viread (tenofovir disoproxil fumarate). These drugs maintain viral control but require lifelong use, often weighing on adherence. Global sales for hepatitis B treatments were around $3.57 billion in 2024.
Analyst Stephanie Kurdach said none of the late-stage candidates follow the established nucleos(t)ide analogue approach. Instead, pharmaceutical companies have tilted toward immune and RNA-based mechanisms that aim to meaningfully reduce viral antigens and restore natural immune responses.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze